What can the health industry expect from a second Trump administration? Tune in to hear what executives should watch over the next few months and years to come.

Key topics include:

• President-elect Trump's healthcare agenda and his focus on deregulation, flexibility and choice, and accessibility
• Potential implications for medicare, the ACA and IRA drug negotiations
• What to watch in the first 100 days

Speakers:
Kelly Griffin, Director, Health Policy and Intelligence Institute
Jenny Colapietro, Consulting Commercial Leader, PwC

Linked materials:
https://www.pwc.com/us/en/industries/health-industries/library/election-2024-trump-health-agenda.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune in as PwC specialists discuss best practices for securing a seat on an emerging company board.
Key topics include:

• Types of emerging companies
• Responsibilities of serving on emerging company boards
• Five strategies for securing a board position
• Importance of industry-specific expertise and continuous learning

Speakers:
Holly Reeves, Partner, Emerging Company Solutions Market Leader, Health Industries, PwC US
Carin Robinson, Director, Governance Insights Center, PwC US
Jenny Colapietro, Consulting Commercial Leader, PwC

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune in as authors of PwC's 2025 Medical Cost Trend Report: Behind the Numbers, discuss key findings and provide what employers should consider to manage rising healthcare costs.

Key points include:

• Cost projections: The highest medical cost trend in 13 years, with an 8% increase for the group market and 7.5% for the individual market
• Key drivers: Inflation, providers' cost-control efforts, increased use of prescription drugs, and new innovative therapies
• Strategic adjustments: Employers should revise benefit plans and consider innovative solutions to manage rising costs while ensuring access to quality care

Speakers:
Thom Bales, Health Services Advisory Leader, PwC
Phil Sclafani, Principal, Pharmaceutical and Life Sciences, PwC
Julian Levin, Principal, Actuarial Leader, PwC
Jenny Colapietro, Consulting Commercial Leader, PwC

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune into this episode of PwC's Next in Health to hear Strategy& Principal, Igor Belokrinitsky, in discussion with PwC Strategy& Director, Rohit Nayak, PwC Strategy& Senior Manager, Sri Murthy Guru and PwC Strategy& Senior Associate, Cailin Hong, on what physicians are seeking from payers, health systems and management services organizations (MSOs), to help improve the practice of medicine. This episode includes:

• Emerging business models and solutions that can enhance the physician experience
• The role of payers and providers in driving physician enablement within the health ecosystem
• Actions health organizations should consider to help support and encourage their physicians

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune in as PwC specialists discuss how emerging companies (private, pre-IPO) are navigating growth in the health industry.

Key topics include:

• The journey and milestones of emerging companies in the life sciences, biotech and medical technology fields, including capital raising, product development and IPO preparation
• Common pitfalls and best practices for managing diverse interests from investors and stakeholders
• Examples of how emerging companies are leveraging AI and other technologies to prioritize programs, design clinical trials and communicate value proposition

Speakers:
Holly Reeves, Health Industries - Emerging Company Solutions Market Leader, PwC US
Christian Jester, Technology, Media & Telecommunications - Emerging Company Solutions Market Leader, PwC US
Jenny Colapietro, Health Industries Vice Chair, PwC, US

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune in as PwC specialists discuss the 2024 outlook for healthcare and how the sector can grow and innovate amid economic challenges and uncertainty.

Key Topics include:

• Major forces impacting the sector: economic pressure, rising costs, labor shortage, and expensive drugs
• Ways to overcome compression and deliver value: industry-wide transformation, tech enabled business model reinvention, transactions and deals to drive transformation, and building trust

Speakers:
Laura Robinette, Health Industries Trust Solutions Leader, PwC, US
Thom Bales, Health Services Leader, PwC, US
Jenny Colapietro, Health Industries Vice Chair, PwC, US

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune in to hear PwC specialists discuss strategies to reinvent the pharma business model and drive growth in the pharmaceutical industry.

Key topics include:

• The headwinds for pharma are real and sustained
• Rethinking the innovation strategy
• Accelerate using AI and analytics
• Lower costs
• M&A as a catalyst for transformation
• Protecting the enterprise

Speakers:

Jenny Colapietro, Health Industries Vice Chair, PwC
Glenn Hunzinger, Pharmaceutical and Life Sciences Leader, PwC
Greg Rotz, Pharmaceutical and Life Sciences Advisory Leader, PwC

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune in to hear PwC Deals leaders discuss preparing for deals in 2024, exploring the current state of the deals market and sharing valuable insights from their newly released 2024 deals outlook. Key topics include:

• Fundamental changes and strategy trends for 2024 and how it’s shaping the health services and pharma landscapes
• The role of the regulators and their impact on deals
• Business model reinvention and the use of new technology to acquire better data and how it’s shaping the deals environment for 2024
• What’s on the horizon: Key success factors for good deal making in 2024

Speakers:
Roel van den Akker, Pharmaceutical and Life Sciences Deals Leader, PwC
Nick Donkar, Health Services Deals Leader, PwC
Jenny Colapietro, Health Industries Vice Chair, PwC
Igor Belokrinitsky, Strategy& Principal, PwC

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.